Keros Therapeutics, Inc. (KROS)
11.61
-0.34
(-2.85%)
USD |
NASDAQ |
Oct 12, 16:00
11.61
0.00 (0.00%)
After-Hours: 18:06
Keros Therapeutics Enterprise Value : -4.947M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | -4.947M |
| October 08, 2026 | -11.09M |
| October 07, 2026 | -19.62M |
| October 06, 2026 | -23.58M |
| October 05, 2026 | -13.47M |
| October 02, 2026 | -16.64M |
| October 01, 2026 | -18.63M |
| September 30, 2026 | -15.85M |
| September 29, 2026 | -20.02M |
| September 28, 2026 | -18.23M |
| September 25, 2026 | -11.49M |
| September 24, 2026 | -12.88M |
| September 23, 2026 | -11.29M |
| September 22, 2026 | -9.309M |
| September 21, 2026 | -14.27M |
| September 18, 2026 | -20.02M |
| September 17, 2026 | -16.64M |
| September 16, 2026 | -28.94M |
| September 15, 2026 | -20.41M |
| September 14, 2026 | -19.62M |
| September 11, 2026 | -22.20M |
| September 10, 2026 | -20.41M |
| September 09, 2026 | -17.64M |
| September 08, 2026 | -20.41M |
| September 04, 2026 | -17.44M |
| Date | Value |
|---|---|
| September 03, 2026 | -21.60M |
| September 02, 2026 | -19.22M |
| September 01, 2026 | -22.39M |
| August 31, 2026 | -22.20M |
| August 28, 2026 | -23.19M |
| August 27, 2026 | -19.22M |
| August 26, 2026 | -21.40M |
| August 25, 2026 | -10.30M |
| August 24, 2026 | -28.14M |
| August 21, 2026 | -23.19M |
| August 20, 2026 | -24.77M |
| August 19, 2026 | -21.80M |
| August 18, 2026 | -31.52M |
| August 17, 2026 | -34.09M |
| August 14, 2026 | -41.63M |
| August 13, 2026 | -30.52M |
| August 12, 2026 | -19.82M |
| August 11, 2026 | -30.92M |
| August 10, 2026 | -29.93M |
| August 07, 2026 | -20.81M |
| August 06, 2026 | -30.72M |
| August 05, 2026 | -43.71M |
| August 04, 2026 | -38.65M |
| August 03, 2026 | -41.43M |
| July 31, 2026 | -42.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Incyte Corp. | 18.17B |
| Viking Therapeutics, Inc. | 2.828B |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.71M |
| Total Expenses (Quarterly) | 28.71M |
| EPS Diluted (Quarterly) | -1.45 |
| Earnings Yield | -31.87% |
| Normalized Earnings Yield | -31.85 |